Butorphanol Nasal Spray CIV
Generic Name and Formulations:
Butorphanol tartrate 1mg/spray; nasal spray.
Various generic manufacturers
Indications for Butorphanol Nasal Spray:
Pain management when opioid analgesia is appropriate.
≥18 years: initially 1 spray in 1 nostril, repeat after 60–90 minutes if needed (Elderly: 90–120 minutes); may repeat in 3–4 hours. Or, may give 1 spray in each nostril, may repeat after 3–4 hours.
<18 years: not recommended.
Head injury. Increased intracranial pressure. Biliary tract surgery. Respiratory, cardiac, renal, or hepatic dysfunction. MI. Ventricular dysfunction. Coronary insufficiency. Hypertension. May precipitate withdrawal in narcotic addicts. Elderly. Labor & delivery. Pregnancy (Cat.C). Nursing mothers.
Potentiates CNS depression with alcohol, other CNS depressants. Nasal vasoconstrictors delay onset. May be antagonized by concomitant (within 30 minutes) sumatriptan nasal spray.
Sedation, dizziness, nasal congestion, insomnia, GI upset, respiratory depression, sweating, hypo- or hypertension, rash, vasodilation, palpitation, tinnitus, respiratory and CNS effects.
Formerly known under the brand name Stadol NS.
Nasal Spray 2.5mL (8–15 sprays)—Contact supplier.
Sign Up for Free e-newsletters
Psychiatry Advisor Articles
- Nomophobia: The Modern-Day Pathology
- Emerging Theories in the Pathophysiology of MDD: Could the Opioid System Be Involved?
- Transdermal Nicotine Boosts Mood and Cognitive Function in Late-Life Depression
- Combination Cognitive Behavioral Therapy With Fluoxetine Effective for Adolescent Depression
- Prazosin May Be Effective as Treatment for Alcohol Use Disorder
- Text Message Reminders Improve Medication Adherence in Bipolar I Disorder
- Improving Medication Adherence in ADHD Lowers Risk for Oppositional Defiant Disorder, Conduct Disorder in Adulthood
- High Suicidality Among Children With ADHD Mediated by Family Functioning, Psychiatry Comorbidities
- Pilot Study Investigates Lithium vs Quetiapine for Bipolar Spectrum Disorder
- How Personalized Hospital Ratings May Drive Patient-Specific Care in the Digital Age